Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES

Addiction

Volumn 113, Issue 8, 2018, Pages 1507-1516

  West, Robert ^a   Evins, A Eden ^b   Benowitz, Neal L ^c   Russ, Cristina ^d   McRae, Thomas ^d   Lawrence, David ^d   St Aubin, Lisa ^d   Krishen, Alok ^e   Maravic, Melissa C ^b   Anthenelli, Robert M ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

^e PAREXEL INTERNATIONAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bupropion; nicotine replacement therapy; placebo; smoking cessation; treatment effects; varenicline

Indexed keywords

AMFEBUTAMONE; PSYCHOTROPIC AGENT; VARENICLINE;

ADULT; AGE; ANXIETY DISORDER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ETHNIC GROUP; FEMALE; HUMAN; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MOOD DISORDER; PROGNOSIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; THERAPY; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGE FACTORS; ANXIETY DISORDERS; BUPROPION; DOUBLE-BLIND METHOD; ETHNIC GROUPS; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MOOD DISORDERS; PROGNOSIS; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SMOKING; SMOKING CESSATION; SMOKING CESSATION AGENTS; TOBACCO USE CESSATION DEVICES; TREATMENT OUTCOME; UNITED STATES; VARENICLINE;

EID: 85044513365     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14208     Document Type: Article

References (34)

1. Anthenelli R. M., Benowitz N. L., West R., St Aubin L., Mcrae T., Lawrence D. et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387: 2507–2520
2. Ockene J. K., Emmons K. M., Mermelstein R. J., Perkins K. A., Bonollo D. S., Voorhees C. C. et al. Relapse and maintenance issues for smoking cessation. Health Psychol 2000; 19: 17–31
3. Faseru B., Nollen N. L., Mayo M. S., Krebill R., Choi W. S., Benowitz N. L. et al. Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. Addict Behav 2013; 38: 1796–1803
4. Vangeli E., Stapleton J., Smit E. S., Borland R., West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction 2011; 106: 2110–2121
5. Zhou X., Nonnemaker J., Sherrill B., Gilsenan A. W., Coste F., Wsest R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav 2009; 34: 365–373
6. Dorner T. E., Trostl A., Womastek I., Groman E. Predictors of short-term success in smoking cessation in relation to attendance at a smoking cessation program. Nicotine Tob Res 2011; 13: 1068–1075
7. Prado G. F., Lombardi E. M., Bussacos M. A., Arrabal-Fernandes F. L., Terra-Filho M., Santos Ude P. A real-life study of the effectiveness of different pharmacological approaches to the treatment of smoking cessation: re-discussing the predictors of success. Clinics (Sao Paulo) 2011; 66: 65–71
8. Apollonio D., Philipps R., Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev 2016; Art. No.: CD010274
9. Hitsman B., Papandonatos G. D., Mcchargue D. E., Demott A., Herrera M. J., Spring B. et al. Past major depression and smoking cessation outcome: a systematic review and meta-analysis update. Addiction 2013; 108: 294–306
10. Borrelli B., Spring B., Niaura R., Hitsman B., Papandonatos G. Influences of gender and weight gain on short-term relapse to smoking in a cessation trial. J Consult Clin Psychol 2001; 69: 511–515
11. Hyland A., Borland R., Li Q., Yong H. H., Mcneill A., Fong G. T. et al. Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control 2006; 15: iii 83–iii 94
12. Gibson J. E., Murray R. L., Borland R., Cummings K. M., Fong G. T., Hammond D. et al. The impact of the United Kingdom's national smoking cessation strategy on quit attempts and use of cessation services: findings from the International Tobacco Control Four Country Survey. Nicotine Tob Res 2010; 12: S64–S71
13. Nakamura M., Oshima A., Ohkura M., Arteaga C., Suwa K. Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clin Ther 2014; 36: 918–927
14. Choi Y. J., Park J. S., Kim U., Lee S. H., Son J. W., Shin D. G. et al. Changes in smoking behavior and adherence to preventive guidelines among smokers after a heart attack. J Geriatr Cardiol 2013; 10: 146–150
15. Gonzales D., Hajek P., Pliamm L., Nackaerts K., Tseng L. J., Mcrae T. D. et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther 2014; 96: 390–396
16. Mckee S. A., Smith P. H., Kaufman M., Mazure C. M., Weinberger A. H. Sex differences in varenicline efficacy for smoking cessation: a meta-analysis. Nicotine Tob Res 2016; 18: 1002–1011
17. Schnoll R. A., Patterson F., Wileyto E. P., Tyndale R. F., Benowitz N., Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009; 92: 6–11
18. Sutherland G., Stapleton J. A., Russell M. A., Jarvis M. J., Hajek P., Belcher M. et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–329
19. Piper M. E., Schlam T. R., Cook J. W., Smith S. S., Bolt D. M., Loh W. Y. et al. Toward precision smoking cessation treatment I. Moderator results from a factorial experiment. Drug Alcohol Depend 2017; 171: 59–65
20. Westover A. N., Kashner T. M., Winhusen T. M., Golden R. M., Nakonezny P. A., Adinoff B. et al. A systematic approach to subgroup analyses in a smoking cessation trial. Am J Drug Alcohol Abuse 2015; 41: 498–507
21. Strong D. R., David S. P., Johnstone E. C., Aveyard P., Murphy M. F., Munafo M. R. Differential efficacy of nicotine replacement among overweight and obese women smokers. Nicotine Tob Res 2015; 17: 855–861
22. Schnoll R. A., Patterson F. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. Drug Alcohol Depend 2009; 104: S94–S99
23. Uhl G. R., Drgon T., Johnson C., Ramoni M. F., Behm F. M., Rose J. E. Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement. Mol Med 2010; 16: 513–526
24. Brose L. S., West R., Stapleton J. A. Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc 2013; 88: 226–233
25. Lerman C., Schnoll R. A., Hawk L. W. Jr., Cinciripini P., George T. P., Wileyto E. P. et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2015; 3: 131–138
26. West R., Hajek P., Stead L., Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299–303
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn; 2000. Available at: http://dsm.psychiatryonline.org/doi/abs/10.1176/appi.books.9780890420249.dsm-iv-tr
28. Posner K., Brown G. K., Stanley B., Brent D. A., Yershova K. V., Oquendo M. A. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266–1277
29. Zigmond A. S., Snaith R. P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361–370
30. Buss A. H., Perry M. The Aggression Questionnaire. J Pers Soc Psychol 1992; 63: 452–459
31. Fagerstrom K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res 2012; 14: 75–78
32. Heckman B. W., Cummings K. M., Kasza K. A., Borland R., Burris J. L., Fong G. T. et al. Effectiveness of switching smoking-cessation medications following relapse. Am J Prev Med 2017; 53: e63–e70
33. Britton J., Arnott D., Mcneill A., Hopkinson N., Physicians Tobacco Advisory Group of the Royal College of Physicians Nicotine without smoke—putting electronic cigarettes in context. BMJ 2016; 353: i1745
34. Kulak J. A., Cornelius M. E., Fong G. T., Giovino G. A. Differences in quit attempts and cigarette smoking abstinence between whites and African Americans in the United States: literature review and results from the International Tobacco Control US Survey. Nicotine Tob Res 2016; 18: S79–S87